68Ga-FAPI-46 PET/CT评估中轴型脊柱关节炎结构损伤与炎症的前瞻性研究
该前瞻性研究于2023年7月至2024年7月纳入22例中轴型脊柱关节炎患者和12名健康志愿者,行68Ga-FAPI-46 PET/CT半定量评估关节摄取。患者脊柱摄取显著高于健康志愿者(p < 0.001),脊柱PET/CT评分与ASDAS、CRP及MRI所示炎症强相关;生物制剂应答者基线脊柱及总关节评分显著高于无应答者。
要点
- 中轴型脊柱关节炎患者脊柱68Ga-FAPI-46摄取显著高于健康志愿者(p < 0.001)。
- 脊柱FAPI PET/CT评分与ASDAS、CRP及MRI所示炎症强相关。
- 生物制剂应答者基线脊柱评分中位36.5 vs 无应答者4.0(p = 0.017)。
核心结论
- 68Ga-FAPI-46 PET/CT有潜力作为一种双功能影像工具,整合CT的结构成像能力与检测炎症的能力。
研究设计与样本
- 前瞻性研究,于2023年7月至2024年7月纳入22例中轴型脊柱关节炎患者和12名健康志愿者。
- 入组时评估疾病活动度及炎症相关参数,随后行68Ga-FAPI-46 PET/CT评估关节FAPI摄取。
- 68Ga-FAPI-46摄取采用三点量表半定量评估,各点评分相加生成FAPI摄取评分。
- 接受生物制剂治疗的患者根据临床随访分为应答者和无应答者。
主要发现
- 与健康志愿者相比,中轴型脊柱关节炎患者在多个关节表现出显著更高的68Ga-FAPI-46摄取,尤其是脊柱(p < 0.001)。
- 脊柱68Ga-FAPI-46 PET/CT评分与ASDAS、CRP等炎症指标及MRI所示炎症强相关。
- 生物制剂应答者基线脊柱68Ga-FAPI-46 PET/CT评分中位36.5 vs 无应答者4.0(p = 0.017)。
- 生物制剂应答者基线总关节68Ga-FAPI-46 PET/CT评分中位53.5 vs 无应答者11.0(p = 0.015),应答者高于无应答者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Axial spondyloarthritis (axSpA) is characterized by active inflammation and structural damage. To date, there is no imaging tool can alone visualize all those changes well. PET/CT imaging with gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) provide extra ability for CT in detecting active inflammation in addition to its advantage in assessing structural damage. This study aims to explore the utility of 68Ga-FAPI-46 PET/CT for assessing active inflammation in axSpA. METHODS: Between July 2023 to July 2024, 22 patients with axSpA and 12 healthy volunteers were prospectively enrolled. Disease activity and parameters associated with inflammation were evaluated at enrollment. Participants then underwent 68Ga-FAPI-46 PET/CT for assessment of FAPI uptake across joints. 68Ga-FAPI-46 uptake was semi-quantitatively evaluated by using a three-point scale. The sum of points was calculated to generate 68Ga-FAPI-46 PET/CT-derived FAPI uptake scores. Patients receiving biologics therapy were grouped as responders or non-responders according to clinical follow-up. RESULTS: Compared to healthy volunteers, patients with axSpA exhibited significantly higher 68Ga-FAPI-46 uptake in several joints, especially in spine (p < 0.001). 68Ga-FAPI-46 PET/CT scores in spine showed strong correlation with the Ankylosing Spondylitis Disease Activity Score (ASDAS), inflammatory indicators such as c-reactive protein (CRP), and inflammation visualized by magnetic resonance imaging (MRI). Biologic responders displayed markedly higher baseline 68Ga-FAPI-46 PET/CT scores in the spine (median: 36.5 vs. 4.0, p = 0.017) and total joints (median: 53.5 vs. 11.0, p = 0.015) compared to non-responders. CONCLUSION: 68Ga-FAPI-46 PET/CT has the potential to serve as a dual-function imaging tool, integrating the structural imaging capabilities of CT with the ability to detect inflammation. CLINICAL TRIAL REGISTRATION: NCT05999643.
引用
- Chen Y, Yu L, Chen S, et al. Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI-46 for evaluation of structural damage and inflammation in axial spondyloarthritis: a prospective study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40310563. doi:10.1007/s00259-025-07310-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。